80 of tN. Use has been prescribed by at least 80% of the amount of medication detected in 38% versus 27%. Simpson et al. reported that the mortality among the 297 and 906 diabetic patients with metformin and pioglitazone was compared to rosiglitazone-treated 1.22 and 0.68 times that of 1902 people with diabetes treated with metformin plus sulfonylurea or risk ratios, however, was significantly BSI-201 different from the unit. Lavery et al. found 73, the rate of fracture of the foot 50 and 12% gr he is, ankles, hips and 45,319 diabetic than in nondiabetic patients 616,921. Schwartz et al. the risk of fracture among 520 women compared to 7397 in comparison, even without diabetes type 2 reported were followed for 5 years, with 256 hip fractures best CONFIRMS. A score of 2.5 was a 6.
1% risk of fracture associated 5 years for women without diabetes at the age of 75 years, but in diabetic women, BIRB 796 the corresponding risk was seen with a T-score of2. 0, which indicates that the threshold for the diagnosis of osteoporosis is used in diabetic patients. Aubert et al. analyzed and a database of medical and pharmacy claims 13 million people, with about 69,047 people and 75,352 receive thiazolidinedione comparator, metformin, exenatide or a sulfonylurea. Adjustment for age, the diagnosis of COPD, asthma, osteoporosis, stroke, and history of fracture, fractures were 55% more likely for women and 26% more likely for M Men treated with a thiazolidinedione, with no difference between rosiglitazone and pioglitazone. New treatments. Huffman et al.
studied HNGF6A, Humanin was analog for neuroprotection studies in Alzheimer’s disease associated Neurotoxizit t ZDF rats. HNGF6A improved insulin sensitivity, and reduces the rate of glucose in the blood. Scranton et al. evaluated the effect of bromocriptine rapidly absorbed with placebo in 113 patients with thiazolidinedione A1C of 7.5%, 0.7% is treated compared to find a report A1C reduction of 0.6% for 52 weeks. Gumbiner et al. administered MB07803, shows an inhibitor of fructose 1,6 bisphosphatase, 42 type 2 diabetic patients with baseline A1C 8.8% and fasting blood glucose of 221 mg / dl for 14 days, 16, 58 and 55 mg / dl reduction in fasting glucose 50, 200 and 400 mg per day, respectively. One third of those receiving 200 mg were dizziness, and H Half of those receiving 400 mg developed vomiting, with an unsupported development lactate 4.
5 mmol / l Migoya et al. Glucokinase Activator MK administered 0599 doses of 25, 50 and 100 mg three times over a period of 1 day to people without diabetes, research related to the dose of glucose down, but hypoglycaemia Mie at least two hours Heren doses. Antagonism of glucocorticoid Of. Rosenstock et al. administered 11 hydroxystro Dehydrogenase type 1 inhibitor, INCB13739, metformin treated type 2 diabetes find no Ver Change in HbA1c in 28 patients who received placebo, but 0.6% and a reduction of 0.5% in 54 patients, the 100 and 200 mg per day performed. Plasma ACTH increased Ht, but remained within the normal range and cortisol were unlocked Changed, suggesting that adrenal insufficiency h Frequently occur with this agent. Asagami et al. selective glucocorticoid administered IS Antagon of, without adversely ADS108297 chtigung effect of progesterone on Mice dietinduced in a model of obesity shows Pr prevention of weight gain and simila.